# EDGAR Filing Document

**Accession Number:** 0001673985
**File Stem:** 0001673985-26-000037
**Filing Date:** 2026-5
**Character Count:** 115191
**Document Hash:** 1667a06e7dbc449588be73c5ea522d64
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001673985-26-000037.hdr.sgml**: 20260508

**ACCESSION NUMBER**: 0001673985-26-000037

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 64

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260508

**DATE AS OF CHANGE**: 20260508

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AdvanSix Inc.
- **CENTRAL INDEX KEY:** 0001673985
- **STANDARD INDUSTRIAL CLASSIFICATION:** PLASTICS, MATERIALS, SYNTH RESINS & NONVULCAN ELASTOMERS [2821]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 812525089
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37774
- **FILM NUMBER:** 26958197

**BUSINESS ADDRESS:**
- **STREET 1:** 300 KIMBALL DRIVE
- **STREET 2:** SUITE 101
- **CITY:** PARSIPPANY
- **STATE:** NJ
- **ZIP:** 07054
- **BUSINESS PHONE:** (973) 526-1800

**MAIL ADDRESS:**
- **STREET 1:** 300 KIMBALL DRIVE
- **STREET 2:** SUITE 101
- **CITY:** PARSIPPANY
- **STATE:** NJ
- **ZIP:** 07054

?xml version='1.0' encoding='ASCII'? asix-20260331

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 10-Q**

---

| | |
|:---|:---|
| (Mark One) | (Mark One) |
| ☒ | **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |

---

 **For the quarterly period ended March 31, 2026** 

or

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from _____ to _____**

**Commission File Number: 1-37774**

---

| |
|:---|
| **AdvanSix Inc.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | |
|:---|:---|
| **Delaware** | **81-2525089** |
| *(State or other jurisdiction of*<br>*incorporation or organization)* | *(I.R.S. Employer Identification No.)* |

---

---

| | |
|:---|:---|
| **300 Kimball Drive, Suite 101, Parsippany, New Jersey** | **07054** |
| *(Address of principal executive offices)* | *(Zip Code)* |

---

**(973) 526-1800**

*(Registrant's telephone number, including area code)*

---

| | | |
|:---|:---|:---|
| Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.01 per share | ASIX | New York Stock Exchange |

---

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes 🗷 No □

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes 🗷 No □

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer 🗷 Accelerated filer □ Non-accelerated filer □ Smaller reporting company ☐ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No 🗷

The registrant had 26,959,036 shares of common stock, $0.01 par value, outstanding at May 1, 2026.

------

**ADVANSIX INC.** 

**FORM 10-Q**

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| <u>[Part I.](#ic60921f4df3846dcbac92b556d4114fe_10)</u> | <u>[FINANCIAL INFORMATION](#ic60921f4df3846dcbac92b556d4114fe_10)</u> | |
| <u>[Item 1.](#ic60921f4df3846dcbac92b556d4114fe_13)</u> | <u>[Financial Statements](#ic60921f4df3846dcbac92b556d4114fe_13)</u> | <u>[3](#ic60921f4df3846dcbac92b556d4114fe_16)</u> |
| | <u>[Condensed Consolidated Statements of Operations for the](#ic60921f4df3846dcbac92b556d4114fe_16)</u><u>three months ended March 31, 2026 and 2025</u><u>[(unaudited)](#ic60921f4df3846dcbac92b556d4114fe_16)</u> | <u>[3](#ic60921f4df3846dcbac92b556d4114fe_16)</u> |
| | <u>[Condensed Consolidated Statements of Comprehensive Income (Loss) for the](#ic60921f4df3846dcbac92b556d4114fe_19)</u><u>three months ended March 31, 2026 and 2025</u><u>[(unaudited)](#ic60921f4df3846dcbac92b556d4114fe_19)</u> | <u>[4](#ic60921f4df3846dcbac92b556d4114fe_19)</u> |
| | <u>[Condensed Consolidated Balance Sheets as of](#ic60921f4df3846dcbac92b556d4114fe_22)March 31, 2026[and](#ic60921f4df3846dcbac92b556d4114fe_22)December 31, 2025[(unaudited)](#ic60921f4df3846dcbac92b556d4114fe_22)</u> | <u>[5](#ic60921f4df3846dcbac92b556d4114fe_22)</u> |
| | <u>[Condensed Consolidated Statements of Cash Flows for the](#ic60921f4df3846dcbac92b556d4114fe_25)</u><u>three months ended March 31, 2026 and 2025</u><u>[(unaudited)](#ic60921f4df3846dcbac92b556d4114fe_25)</u> | <u>[6](#ic60921f4df3846dcbac92b556d4114fe_25)</u> |
| | <u>[Condensed Consolidated Statements of Stockholders' Equity for the](#ic60921f4df3846dcbac92b556d4114fe_28)three months ended March 31, 2026 and 2025[(unaudited)](#ic60921f4df3846dcbac92b556d4114fe_28)</u> | <u>[7](#ic60921f4df3846dcbac92b556d4114fe_28)</u> |
| | <u>[Notes to Condensed Consolidated Financial Statements (unaudited)](#ic60921f4df3846dcbac92b556d4114fe_31)</u> | <u>[8](#ic60921f4df3846dcbac92b556d4114fe_31)</u> |
| <u>[Item 2.](#ic60921f4df3846dcbac92b556d4114fe_100)</u> | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#ic60921f4df3846dcbac92b556d4114fe_100)</u> | <u>[16](#ic60921f4df3846dcbac92b556d4114fe_100)</u> |
| <u>[Item 3.](#ic60921f4df3846dcbac92b556d4114fe_157)</u> | <u>[Quantitative and Qualitative Disclosures About Market Risk](#ic60921f4df3846dcbac92b556d4114fe_157)</u> | <u>[25](#ic60921f4df3846dcbac92b556d4114fe_157)</u> |
| <u>[Item 4.](#ic60921f4df3846dcbac92b556d4114fe_160)</u> | <u>[Controls and Procedures](#ic60921f4df3846dcbac92b556d4114fe_160)</u> | <u>[25](#ic60921f4df3846dcbac92b556d4114fe_160)</u> |
| <u>[Part II.](#ic60921f4df3846dcbac92b556d4114fe_163)</u> | <u>[OTHER INFORMATION](#ic60921f4df3846dcbac92b556d4114fe_163)</u> | <u>[26](#ic60921f4df3846dcbac92b556d4114fe_163)</u> |
| <u>[Item 1.](#ic60921f4df3846dcbac92b556d4114fe_166)</u> | <u>[Legal Proceedings](#ic60921f4df3846dcbac92b556d4114fe_166)</u> | <u>[26](#ic60921f4df3846dcbac92b556d4114fe_166)</u> |
| <u>[Item 1A.](#ic60921f4df3846dcbac92b556d4114fe_169)</u> | <u>[Risk Factors](#ic60921f4df3846dcbac92b556d4114fe_169)</u> | <u>[26](#ic60921f4df3846dcbac92b556d4114fe_169)</u> |
| <u>[Item 2.](#ic60921f4df3846dcbac92b556d4114fe_172)</u> | <u>[Unregistered Sales of Equity Securities and Use of Proceeds](#ic60921f4df3846dcbac92b556d4114fe_172)</u> | <u>[26](#ic60921f4df3846dcbac92b556d4114fe_172)</u> |
| <u>[Item 5.](#ic60921f4df3846dcbac92b556d4114fe_175)</u> | <u>[Other Information](#ic60921f4df3846dcbac92b556d4114fe_175)</u> | <u>[27](#ic60921f4df3846dcbac92b556d4114fe_175)</u> |
| <u>[Item 6.](#ic60921f4df3846dcbac92b556d4114fe_181)</u> | <u>[Exhibits](#ic60921f4df3846dcbac92b556d4114fe_181)</u> | <u>[28](#ic60921f4df3846dcbac92b556d4114fe_181)</u> |
| | <u>[Signature](#ic60921f4df3846dcbac92b556d4114fe_184)</u> | <u>[29](#ic60921f4df3846dcbac92b556d4114fe_184)</u> |

---

------

**PART I. FINANCIAL INFORMATION**

**ITEM 1. FINANCIAL STATEMENTS**

**ADVANSIX INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**(Unaudited)**

**(Dollars in thousands, except share and per share amounts)**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| Sales | $404183 | $377791 |
| Costs, expenses and other: |  |  |
| &nbsp;&nbsp;Cost of goods sold | 400381 | 324320 |
| &nbsp;&nbsp;Selling, general and administrative expenses | 22518 | 23409 |
| &nbsp;&nbsp;Interest expense, net | 2430 | 1541 |
| &nbsp;&nbsp;Other non-operating income, net | (469) | (408) |
| Total costs, expenses and other | 424860 | 348862 |
| Income (loss) before taxes | (20677) | 28929 |
| Income tax expense (benefit) | (5131) | 5585 |
| Net income (loss) | $(15546) | $23344 |
| Earnings per common share |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $(0.58) | $0.87 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $(0.58) | $0.86 |
| Weighted average common shares outstanding |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | 26980742 | 26838146 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | 26980742 | 27289144 |

---

**See accompanying notes to Condensed Consolidated Financial Statements.**

------

**ADVANSIX INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)**

**(Unaudited)**

**(Dollars in thousands)**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| Net income (loss) | $(15546) | $23344 |
| Foreign exchange translation adjustment | 8 | 11 |
| Cash-flow hedges |  | 7 |
| Other comprehensive income, net of tax | 8 | 18 |
| Comprehensive income (loss) | $(15538) | $23362 |

---

**See accompanying notes to Condensed Consolidated Financial Statements.**

------

**ADVANSIX INC.**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(Unaudited)**

**(Dollars in thousands, except share and per share amounts)**

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| **ASSETS** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;Cash and cash equivalents | $17574 | $19766 |
| &nbsp;&nbsp;Accounts and other receivables – net | 207607 | 154102 |
| &nbsp;&nbsp;Inventories – net | 201358 | 236495 |
| &nbsp;&nbsp;Taxes receivable | 22092 | 21605 |
| &nbsp;&nbsp;Other current assets | 5360 | 8639 |
| Total current assets | 453991 | 440607 |
| Property, plant and equipment – net | 965087 | 963718 |
| Operating lease right-of-use assets | 155044 | 164494 |
| Goodwill | 56192 | 56192 |
| Intangible assets | 39333 | 40095 |
| Other assets | 41106 | 41042 |
| Total assets | $1710753 | $1706148 |
| **LIABILITIES** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $284334 | $284016 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | 30546 | 45945 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes payable | 579 | 1100 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities – short-term | 43670 | 44354 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income and customer advances | 11303 | 14536 |
| Total current liabilities | 370432 | 389951 |
| Deferred income taxes | 150641 | 154061 |
| Operating lease liabilities – long-term | 112690 | 121201 |
| Line of credit – long-term | 270000 | 215000 |
| Other liabilities | 10701 | 10719 |
| Total liabilities | 914464 | 890932 |
| **COMMITMENTS AND CONTINGENCIES (Note 9)** |  |  |
| **STOCKHOLDERS' EQUITY** |  |  |
| Common stock, par value $0.01; 200,000,000 shares authorized; 33,345,325 shares issued and 26,959,036 outstanding at March 31, 2026; 33,177,824 shares issued and 26,864,035 outstanding at December 31, 2025 | 334 | 332 |
| Preferred stock, par value $0.01; 50,000,000 shares authorized and 0 shares issued and outstanding at March 31, 2026 and December 31, 2025 |  |  |
| Treasury stock at par (6,386,289 shares at March 31, 2026; 6,313,789 shares at December 31, 2025) | (64) | (63) |
| Additional paid-in capital | 144066 | 142932 |
| Retained earnings | 642949 | 663019 |
| Accumulated other comprehensive income | 9004 | 8996 |
| Total stockholders' equity | 796289 | 815216 |
| Total liabilities and stockholders' equity | $1710753 | $1706148 |

---

**See accompanying notes to Condensed Consolidated Financial Statements.**

------

**ADVANSIX INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(Unaudited)**

**(Dollars in thousands)**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| **Cash flows from operating activities:** |  |  |
| Net income (loss) | $(15546) | $23344 |
| Adjustments to reconcile net income to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;Depreciation and amortization | 20958 | 19178 |
| &nbsp;&nbsp;(Gain) loss on disposal of assets | 4 | (210) |
| &nbsp;&nbsp;Deferred income taxes | (3420) | 4054 |
| &nbsp;&nbsp;Stock-based compensation | 2045 | 1978 |
| &nbsp;&nbsp;Amortization of deferred financing fees | 123 | 155 |
| &nbsp;&nbsp;Changes in assets and liabilities, net of business acquisitions: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts and other receivables | (53497) | (33652) |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories | 35137 | (10471) |
| &nbsp;&nbsp;&nbsp;&nbsp;Taxes receivable | (487) | 448 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 16162 | 19362 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes payable | (521) | 1543 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | (15163) | (4949) |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income and customer advances | (3233) | (10956) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other assets and liabilities | 2106 | 1619 |
| Net cash provided by (used for) operating activities | (15332) | 11443 |
| **Cash flows from investing activities:** |  |  |
| Expenditures for property, plant and equipment | (35936) | (34062) |
| Other investing activities | (227) | (2732) |
| Net cash used for investing activities | (36163) | (36794) |
| **Cash flows from financing activities:** |  |  |
| Borrowings from line of credit | 139500 | 118500 |
| Repayments of line of credit | (84500) | (98500) |
| Principal payments of finance leases | (263) | (247) |
| Dividend payments | (4313) | (4290) |
| Purchase of treasury stock | (1275) | (1486) |
| Issuance of common stock | 154 | 154 |
| Net cash provided by financing activities | 49303 | 14131 |
| Net change in cash and cash equivalents | (2192) | (11220) |
| Cash and cash equivalents at beginning of period | 19766 | 19564 |
| Cash and cash equivalents at the end of period | $17574 | $8344 |
| Supplemental non-cash investing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Capital expenditures included in accounts payable | $11006 | $14605 |
| Supplemental cash activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for interest | $2307 | $584 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for income taxes, net of refund | $247 | $— |

---

**See accompanying notes to Condensed Consolidated Financial Statements.**

------

**ADVANSIX INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY**

**(Unaudited)**

**(Dollars in thousands)**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | **Additional Paid-In Capital** | **Retained Earnings** | **Treasury Stock** | **Accumulated Other Comprehensive Income (Loss)** | **Total Equity** |
| | **Shares** | **Amount** | **Additional Paid-In Capital** | **Retained Earnings** | **Treasury Stock** | **Accumulated Other Comprehensive Income (Loss)** | **Total Equity** |
| Balance at December 31, 2025 | 33177824 | $332 | $142932 | $663019 | $(63) | $8996 | $815216 |
| Net loss |  |  |  | (15546) |  |  | (15546) |
| Comprehensive income |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Foreign exchange translation adjustments |  |  |  |  |  | 8 | 8 |
| Other comprehensive income, net of tax |  |  |  |  |  | 8 | 8 |
| Issuance of common stock | 167501 | 2 | 152 |  |  |  | 154 |
| Purchase of treasury stock (72,500 shares) |  |  | (1274) |  | (1) |  | (1275) |
| Stock-based compensation |  |  | 2045 |  |  |  | 2045 |
| Dividends |  |  | 211 | (4524) |  |  | (4313) |
| Balance at March 31, 2026 | **33345325** | $**334** | $**144066** | $**642949** | $**(64)** | $**9004** | $**796289** |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | **Additional Paid-In Capital** | **Retained Earnings** | **Treasury Stock** | **Accumulated Other Comprehensive Income (Loss)** | **Total Equity** |
| | **Shares** | **Amount** | **Additional Paid-In Capital** | **Retained Earnings** | **Treasury Stock** | **Accumulated Other Comprehensive Income (Loss)** | **Total Equity** |
| Balance at December 31, 2024 | 32989165 | $330 | $136872 | $631541 | $(63) | $5970 | $774650 |
| Net income |  |  |  | 23344 |  |  | 23344 |
| Comprehensive income |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Foreign exchange translation adjustments |  |  |  |  |  | 11 | 11 |
| &nbsp;&nbsp;Cash-flow hedges |  |  |  |  |  | 7 | 7 |
| Other comprehensive income, net of tax |  |  |  |  |  | 18 | 18 |
| Issuance of common stock | 124214 | 1 | 153 |  |  |  | 154 |
| Purchase of treasury stock (53,432 shares) |  |  | (1486) |  |  |  | (1486) |
| Stock-based compensation |  |  | 1978 |  |  |  | 1978 |
| Dividends |  |  | 160 | (4450) |  |  | (4290) |
| Balance at March 31, 2025 | **33113379** | $**331** | $**137677** | $**650435** | $**(63)** | $**5988** | $**794368** |

---

**See accompanying notes to Condensed Consolidated Financial Statements.**

------

**ADVANSIX INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts and as otherwise noted)**

**1. Organization, Operations and Basis of Presentation**

***Description of Business***

AdvanSix Inc. ("AdvanSix," the "Company," "we" or "our") is a vertically integrated chemistry company that produces essential materials for diverse end markets. Our value chain of our five U.S.-based manufacturing facilities plays a critical role in global supply chains and enables us to innovate and deliver essential products for our customers across building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives, electronics and other end markets. Guided by our core values of Safety, Integrity, Accountability and Respect, AdvanSix strives to deliver best-in-class customer experiences and differentiated products in the industries of nylon solutions, plant nutrients and chemical intermediates.

***Basis of Presentation***

The Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and with the instructions to Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited Condensed Consolidated Financial Statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of the Company's financial position as of March 31, 2026, and its results of operations for the three months ended March 31, 2026 and 2025 and cash flows for the three months ended March 31, 2026 and 2025. The year-end Condensed Consolidated Balance Sheet data was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the full fiscal year. These financial statements should be read in conjunction with the Company's Annual Report on Form 10-K for the year ended December 31, 2025. All intercompany transactions have been eliminated.

Certain prior period amounts have been reclassified for consistency with the current period presentation.

It is our practice to establish actual quarterly closing dates using a predetermined fiscal calendar, which requires our businesses to close their books on a Saturday in order to minimize the potentially disruptive effects of quarterly closing on our business processes. Historically, the effects of this practice have generally not been significant to reported results for any quarter and only existed within a reporting year. In the event that differences in actual closing dates are material to year-over-year comparisons of quarterly or year-to-date results, we will provide the appropriate disclosures. Our actual closing dates for the three months ended March 31, 2026 and 2025 were April 4, 2026 and March 29, 2025, respectively, which resulted in six additional reporting days in the current year period from our normal quarterly closing procedures.

Liabilities to creditors to whom we have issued checks that remained outstanding at March 31, 2026 and December 31, 2025 aggregated to $9.0 million and $4.9 million, respectively. These were included in Cash and cash equivalents and Accounts payable in the Condensed Consolidated Balance Sheets.

As of March 31, 2026, the Company has repurchased a total of 6,386,289 shares of common stock, including 1,140,833 shares withheld to cover tax withholding obligations in connection with the vesting of awards, for an aggregate of $195.4 million at a weighted average market price of $30.59 per share. As of March 31, 2026, approximately $62.0 million remained available for share repurchases under the current authorization approved by the Company's Board of Directors (the "Board") on February 17, 2023. During the period April 1, 2026 through May 1, 2026, no additional shares were repurchased for tax withholding obligations or under the currently authorized repurchase program.

Repurchases may be made from time to time on the open market in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including through the use of trading plans intended to qualify under Rule 10b5-1 of the Exchange Act. The size and timing of these repurchases will depend on pricing, market and economic conditions, legal and contractual requirements and other factors. The share repurchase program has no expiration date and may be modified, suspended or discontinued at any time. The par value of the shares repurchased is applied to Treasury stock and the excess of the purchase price over par value is applied to Additional paid-in capital.

**2. Recent Accounting Pronouncements**

------

**ADVANSIX INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts and as otherwise noted)**

**Recent Accounting Pronouncements** – The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs") issued by the Financial Accounting Standards Board ("FASB"). ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on our consolidated financial position or results of operations.

On December 8, 2025, the FASB issued ASU No. 2025-11: Interim Reporting (Topic 270), Narrow Scope Improvements. The amendments in this ASU provide a comprehensive list of interim disclosures that are required by GAAP. The amendments also clarify the applicability of Topic 270, the types of interim reporting, and the form and content of interim financial statements in accordance with GAAP to enhance consistency in interim reporting for all entities. The update is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027 for public business entities. Early adoption is permitted. The amendments in this update can be applied either prospectively or retrospectively to any or all prior periods presented in the financial statements. The Company is evaluating the pronouncement and does not expect adoption to have a material impact on its consolidated financial position or results of operations.

On December 4, 2025, the FASB issued ASU No. 2025-10: Accounting for Government Grants Received by Business Entities. The amendments in this ASU establish the accounting for a government grant received. The amendments require that a grant received should not be recognized until (1) it is probable that (a) an entity will comply with conditions attached to the grant and (b) the grant will be received and (2) an entity meets the recognition guidance for a grant related to an asset or to income. The amendments require that a grant related to an asset be recognized on the balance sheet as the entity incurs the related costs for which the grant is intended to compensate, either as (1) deferred income (the deferred income approach) or (2) an adjustment to the cost basis in determining the carrying amount of the asset (the cost accumulation approach). A grant related to income and a grant related to an asset for which the deferred income approach is elected should be recognized in earnings on a systematic and rational basis over the periods in which an entity recognizes as expenses the costs for which the grant is intended to compensate. The amendments require that an entity present a grant related to income and a grant related to an asset for which the deferred income is elected as part of earnings either (1) separately under a general heading such as other income or (2) deducted from the related expense. In addition, the amendments require that an entity provide disclosures, including the nature of the government grant received, the accounting policies used to account for the grant, and significant terms and conditions of the grant. For public business entities, this update is effective for annual reporting periods beginning after December 15, 2028, and interim reporting periods within those annual reporting periods. Early adoption is permitted in both interim and annual reporting periods in which financial statements have not yet been issued or made available for issuance. The amendments in this ASU require that a business entity apply the guidance using a modified prospective approach, a modified retrospective approach or a retrospective approach to all government grants through a cumulative effect adjustment to the opening balance of retained earnings as of the beginning of the earliest period presented. The Company is evaluating the pronouncement and does not expect adoption to have a material impact on its consolidated financial position or results of operations.

In August 2025, the FASB issued ASU 2025-05, Financial Instruments – Credit Losses (Topic 326): Practical Expedient for Measuring Expected Credit Losses on Certain Financial Assets. The amendments in this ASU provide a simplified approach for estimating credit losses on certain financial assets, including current accounts receivable, by permitting entities to elect a practical expedient when measuring expected credit losses. Under current guidance, when estimating expected credit losses, an entity must (1) consider not only historical loss experience but also adjust that information to reflect current conditions and reasonable and supportable forecasts and (2) include a measure of expected credit loss even if that risk is remote. The amendments in this ASU allow an entity, as a practical expedient, to: (1) Assume that current conditions as of the balance sheet date will remain unchanged over the remaining life of the financial asset; and (2) continue to adjust historical loss information to reflect current conditions to the extent that historical information does not already do so. The amendments are effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual periods. The Company adopted ASU 2025-05 effective January 1, 2026. The adoption did not have a material impact on the Company's consolidated financial position or results of operations.

In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The amendments in this ASU require disclosure, in the notes to the financial statements, of specified information about certain costs and expenses. The amendments require that at each interim and annual reporting period an entity will: (1) disclose the amounts of (a) purchases of inventory, (b) employee compensation, (c) depreciation, (d) intangible asset amortization, and (e) depreciation, depletion, and amortization recognized as part of oil-and gas-producing activities (or other amounts of depletion expense) included in each relevant expense caption. A relevant expense caption is an expense caption presented on the face of the income statement within continuing operations that contains any of the expense categories listed in (a)-(e); (2) include certain amounts that are already required to be disclosed under current generally accepted accounting principles (GAAP) in the same disclosure as other disaggregation requirements; (3) disclose a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively; and (4) disclose the total amount of selling expense and, in annual reporting

------

**ADVANSIX INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts and as otherwise noted)**

periods, an entity's definition of selling expense. The guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The amendments in this ASU should be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to any or all prior periods presented in the financial statements. The Company is evaluating the pronouncement and does not expect adoption to have a material impact on the Company's consolidated financial position or results of operations.

**3. Revenues**

***Revenue Recognition***

AdvanSix serves approximately 375 customers annually, primarily in the United States, spanning a wide variety of industries worldwide. For each of the three months ended March 31, 2026 and 2025, the Company's ten largest customers accounted for approximately 38% of total sales.

We typically sell to customers under master service agreements, with primarily one-year terms, or by purchase orders. We have historically experienced low customer turnover and have long-standing customer relationships, which span decades. Our largest customer is Shaw Industries Group, Inc. ("Shaw"), a significant consumer of caprolactam and Nylon 6 resin, to whom we sell under a long-term agreement. For the three months ended March 31, 2026 and 2025, the Company's sales to Shaw were 9% and 10% of our total sales, respectively.

The Company's revenue by product line, and related approximate percentage of total sales, for the three months ended March 31, 2026 and 2025 were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2026** | **2025** | **2025** |
| Nylon | $88467 | 22% | $88369 | 23% |
| Caprolactam | 67768 | 17% | 67432 | 18% |
| Plant Nutrients | 140635 | 35% | 128240 | 34% |
| Chemical Intermediates | 107313 | 26% | 93750 | 25% |
| Total | $404183 | 100% | $377791 | 100% |

---

The Company's revenues by geographic area, and related approximate percentage of total sales, for the three months ended March 31, 2026 and 2025 were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2026** | **2025** | **2025** |
| United States | $335996 | 83% | $320447 | 85% |
| International\* | 68187 | 17% | 57344 | 15% |
| Total | $404183 | 100% | $377791 | 100% |

---

*\* Predominantly Latin America, EMEA and Canada.*

***Deferred Income and Customer Advances***

The Company defers revenues when cash payments are received in advance of our performance. Below is a roll-forward of Deferred income and customer advances for the three months ended March 31, 2026:

---

| | |
|:---|:---|
| Opening balance January 1, 2026 | $14536 |
| Additional cash advances |  |
| Less amounts recognized in revenues | (3233) |
| Ending balance March 31, 2026 | $11303 |

---

------

**ADVANSIX INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts and as otherwise noted)**

The Company expects to recognize as revenue the March 31, 2026 ending balance of Deferred income and customer advances which are predominantly driven by our ammonium sulfate pre-buy program, within one year or less.

**4. Earnings Per Share**

The computation of basic and diluted earnings per share ("EPS") is based on Net income (loss) divided by the basic weighted average number of common shares outstanding and, where appropriate, diluted weighted average number of common shares outstanding, respectively. The details of the basic and diluted EPS calculations for the three months ended March 31, 2026 and 2025 were as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| **Basic** |  |  |
| Net income (loss) | $(15546) | $23344 |
| Weighted average common shares outstanding | 26980742 | 26838146 |
| EPS – Basic | $(0.58) | $0.87 |
| **Diluted** |  |  |
| Dilutive effect of equity awards and other stock-based holdings |  | 450998 |
| Weighted average common shares outstanding | 26980742 | 27289144 |
| EPS – Diluted | $(0.58) | $0.86 |

---

Where appropriate, diluted EPS is computed based upon the weighted average number of common shares outstanding for the period plus the dilutive effect of common stock equivalents using the treasury stock method and the average market price of our common stock for the period.

Where appropriate, the diluted EPS calculations exclude the effect of stock options when the options' assumed proceeds exceed the average market price of the common shares during the period. The anti-dilutive common stock equivalents outstanding at the three months ended March 31, 2026 and 2025 were as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| Options and stock equivalents | 853891 | 684374 |

---

Dividend activity for the three months ended March 31, 2026 and 2025 was as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| Cash dividends declared per share | $0.16 | $0.16 |
| Aggregate dividends paid to shareholders | $4313 | $4290 |

---

**5. Accounts and Other Receivables** – **Net**

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| Accounts receivables | $207060 | $153059 |
| Other | 887 | 1438 |
| Total accounts and other receivables | 207947 | 154497 |
| Less – allowance for credit losses | (340) | (395) |
| Total accounts and other receivables – net | $207607 | $154102 |

---

**6. Inventories**

------

**ADVANSIX INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts and as otherwise noted)**

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| Raw materials | $91824 | $116248 |
| Semi-finished and finished goods | 131773 | 167498 |
| Spares and other | 33185 | 32877 |
|  | 256782 | 316623 |
| Reduction to LIFO cost basis | (55424) | (80128) |
| Total inventories | $201358 | $236495 |

---

Substantially all of the Company's inventories at March 31, 2026 and December 31, 2025 are valued at the lower of cost or market using the last-in, first-out ("LIFO") method. However, approximately 5% was valued at average cost using the first-in, first-out ("FIFO") method at March 31, 2026.

The excess of replacement cost over the carrying value of total inventories subject to LIFO was $68.2 million and $61.3 million at March 31, 2026 and December 31, 2025, respectively.

**7. Leases**

The Company determines if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use assets ("ROU"), Operating lease liabilities – short-term, and Operating lease liabilities – long-term in our Condensed Consolidated Balance Sheets. Finance leases are included in Property, plant and equipment – net, Accounts payable, and Other liabilities in our Condensed Consolidated Balance Sheets.

The components of lease expense were as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| Finance lease cost: |  |  |
| &nbsp;&nbsp;Amortization of right-of-use asset | $285 | $254 |
| &nbsp;&nbsp;Interest on lease liabilities | 38 | 41 |
| &nbsp;&nbsp;Total finance lease cost | 323 | 295 |
| Operating lease cost | 13296 | 13078 |
| Short-term lease cost | 1837 | 796 |
| Total lease cost | $15456 | $14169 |

---

As of March 31, 2026, we have no additional operating or finance leases that have not yet commenced.

**8. Goodwill and Intangible Assets**

Intangible assets with finite lives acquired through a business combination are recorded at fair value, less accumulated amortization. Customer relationships and trade-names are amortized on a straight-line basis over their expected useful lives of 15 to 20 years and 5 years, respectively.

*<u>Goodwill</u>*

There was no change in the carrying amount of goodwill for the three months ended March 31, 2026.

To determine if goodwill is potentially impaired, we may perform either a qualitative assessment to determine whether it is more likely than not that the fair value is less than the carrying value or a quantitative assessment. The Company most recently performed a qualitative assessment in the fourth quarter of 2025 whereby we considered the enterprise value from the previous quantitative test (including the underlying excess fair value over carrying value), macroeconomic conditions (including changes in interest and discount rates), industry and market considerations, recent and projected financial performance, as well as other factors. The Company concluded that it was not more likely than not that an impairment of the goodwill balances existed.

------

**ADVANSIX INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts and as otherwise noted)**

Our qualitative analysis reflects our best estimates of the impacts of the cyclical nature of the industries in which we operate, as well as the cycles of fluctuating supply and demand for each of our products resulting in changes in selling prices and margins. It is possible that in the future there may be changes in industry trends, estimates and assumptions, including the timing and amount of future cash flows, margins, growth rates, market participant assumptions, comparable benchmark companies and related multiples and discount rates, which could impact estimates of fair value. Significant and adverse changes to any one or more of the above-noted estimates and assumptions could result in an impairment.

*<u>Finite-Lived Intangible Assets</u>*

Intangible assets subject to amortization were as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
| | **Gross Carrying Amount** | **Accumulated Amortization** | **Net Book Value** | **Gross Carrying Amount** | **Accumulated Amortization** | **Net Book Value** |
| Customer relationships | $36820 | $(8049) | $28771 | $36820 | $(7572) | $29248 |
| Licenses | 18451 | (8072) | 10379 | 18451 | (7842) | 10609 |
| Trade names | 1100 | (917) | 183 | 1100 | (862) | 238 |
| &nbsp;&nbsp;Total | $56371 | $(17038) | $39333 | $56371 | $(16276) | $40095 |

---

For each of the three months ended March 31, 2026 and March 31, 2025, the Company recorded amortization expense on intangible assets of $0.8 million.

**9. Commitments and Contingencies**

The Company is subject to a number of lawsuits, investigations and disputes, some of which may involve substantial amounts claimed, arising out of the conduct of the Company or other third-parties in the normal and ordinary course of business. A liability is recognized for any contingency that is probable of occurrence and reasonably estimable. The Company continually assesses the likelihood of adverse judgments or outcomes in these matters, as well as potential ranges of possible losses, based on an analysis of each matter with the assistance of legal counsel and, if applicable, other experts.

Given the uncertainty inherent in such lawsuits, investigations and disputes, the Company does not believe it is possible to develop estimates of reasonably possible loss in excess of current accruals for these matters. Considering the Company's past experience and existing accruals, the Company does not expect the outcome of these matters, either individually or in the aggregate, to have a material adverse effect on the Company's consolidated financial position or results of operations. Potential liabilities are subject to change due to new developments, changes in settlement strategy or the impact of evidentiary requirements, which could cause the Company to pay damage awards or settlements (or become subject to equitable remedies) that could have a material adverse effect on the Company's consolidated results of operations, balance sheet and/or operating cash flows in the periods recognized or paid.

We assumed from Honeywell International Inc. ("Honeywell") all health, safety and environmental ("HSE") liabilities and compliance obligations related to the past and future operations of our current business, as well as all HSE liabilities associated with the three manufacturing locations assumed from Honeywell that are used in our current operations, including any cleanup or other liabilities related to any contamination that may have occurred at such locations in the past. Honeywell retained all HSE liabilities related to former business locations or the operation of our former businesses. Although we have ongoing environmental remedial obligations at certain of our facilities, in the past three years, the associated remediation costs have not been material, and we do not expect our known remediation costs to have a material adverse effect on the Company's consolidated financial position or results of operations.

**10. Income Taxes**

The provision (benefit) for income taxes was ($5.1 million) and $5.6 million for the three months ended March 31, 2026 and 2025, respectively, resulting in an effective tax rate of 24.8% and 19.3%, respectively.

------

**ADVANSIX INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts and as otherwise noted)**

The Company's provision (benefit) for income taxes in interim periods is computed by applying an estimated annual effective tax rate against Income (loss) before taxes for the period in addition to recording any tax effects of discrete items for the quarter. The Company's effective tax rate for the three months ended March 31, 2026 and 2025 differed from the U.S. federal statutory rate due to state taxes and executive compensation deduction limitations which generally increase the rate, offset by research tax credits and the foreign-derived deduction eligible income (FDDEI) deduction (formerly known as the foreign-derived intangible income (FDII) deduction) that generally decrease the rate. During the three months ended March 31, 2025, discrete tax adjustments recorded in the quarter related to Internal Revenue Code (IRC) Section 45Q tax credits of $1.8 million, offset slightly by state tax legislation changes, resulted in a net 5.8% decrease on the rate.

On July 4, 2025, the One Big Beautiful Bill Act (the "Act") was enacted into law which includes numerous tax provisions affecting businesses, including the reinstatement of full expensing of domestic research and experimental expenditures, modification of the limitation on business interest and making permanent full expensing for certain business property. Several of the major business provisions in the Act became effective in 2025 while other business tax changes are effective for the 2026 tax year. The major business provisions in the Act reduced our cash taxes in 2025 and are expected to reduce our cash taxes in 2026 and future periods.

**11. Supplier Finance Programs**

The Company has entered into a supply chain finance program with a financial intermediary providing participating suppliers the option to be paid by the intermediary earlier than the original invoice due date. AdvanSix's responsibility is limited to making payments to the intermediary based upon payment terms negotiated with the suppliers, regardless of whether the intermediary pays the supplier in advance of the original due date. The Company's payment terms with suppliers are consistent, regardless of whether a vendor participates in the supply chain finance program or not. All related agreements are terminable by either party upon at least 30 days' notice.

The total amount due to the financial intermediary to settle supplier invoices under the Company's supply chain finance program was approximately $11.0 million as of March 31, 2026 and approximately $9.0 million as of December 31, 2025. These amounts outstanding are included in Accounts payable.

**12. Segment Related Information**

The Company has concluded that it is a single operating segment and a single reportable segment: chemical manufacturing. Its larger manufacturing sites are vertically integrated and leverage cross-plant resources, including centralized supply chain and procurement functions. This production process uses one key raw material, cumene, as the input to products produced for sale through the sales channels and end markets the Company serves. Production rates and output volumes are managed across locations to align with the Company's overall operating plan. Additionally, the Company's operating results, which are evaluated regularly to make decisions about resource allocation and performance assessment by the chief operating decision maker ("CODM"), our CEO and President, are on a consolidated basis.

The chemical manufacturing segment derives its revenues by innovating and delivering essential products in the industries of nylon solutions, plant nutrients, and chemical intermediates to its customers in a wide variety of end markets and applications, such as building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives and electronics.

The CODM's performance assessment and resource allocation for the chemical manufacturing segment is based on net income which is also reported on the income statement as net income, the measure of segment assets which is also reported on the balance sheet as total assets, and capital expenditures which is also reported in management's discussion and analysis.

The CODM uses net income generated from segment assets in deciding whether to reinvest profits into the segment or into other parts of the entity, such as for acquisitions or to pay dividends. The CODM also uses net income to monitor budget versus actual results. Monitoring budgeted versus actual results is used in assessing performance of the segment and in establishing management's compensation. Lastly, the CODM uses capital expenditures to estimate the cash-generating potential and cash requirements of the segment.

Significant expense information reviewed by the CODM was as follows (in thousands):

------

**ADVANSIX INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**(Dollars in thousands, except share and per share amounts and as otherwise noted)**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Revenue | $404183 | $377791 |
| Less: |  |  |
| &nbsp;&nbsp;Variable costs of goods sold \* | 217703 | 152903 |
| &nbsp;&nbsp;Plant costs | 128592 | 121853 |
| &nbsp;&nbsp;Freight and distribution costs | 51242 | 47403 |
| &nbsp;&nbsp;Selling, general, and administrative expense | 22518 | 23409 |
| &nbsp;&nbsp;Other segment items \*\* | (326) | 8879 |
| Segment net income | $(15546) | $23344 |

---

*\*Variable costs of goods sold includes the raw material costs associated with volumes sold during the period as well as insurance settlement proceeds, when applicable.*

*\*\*Other segment items include research and development expense, interest income and expense, capitalized interest, other non-operating expense, and income tax expense.*

**13. Subsequent Events**

*<u>Dividends</u>*

As announced on May 8, 2026, the Board declared a quarterly cash dividend of $0.16 per share on the Company's common stock, payable on June 2, 2026 to stockholders of record as of the close of business on May 19, 2026.

------

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

The following discussion and analysis of the financial condition and results of operations, of AdvanSix Inc. ("AdvanSix," the "Company," "we" or "our"), which we refer to as our "MD&A," should be read in conjunction with the Condensed Consolidated Financial Statements and the notes thereto contained in this Quarterly Report on Form 10-Q (this "Form 10-Q"), as well as the MD&A section included in our Annual Report on Form 10-K for the year ended December 31, 2025 ("2025 Form 10-K"). Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties. Actual results and the timing of events may differ materially from those contained in these forward-looking statements due to a number of factors that can affect our performance in both the near- and long-term, including those incorporated by reference in Item 1A of Part II of this Form 10-Q as such factors may be revised or supplemented in subsequent filings with the SEC, as well as those discussed in the section entitled "Note Regarding Forward-Looking Statements" below.

**Note Regarding Forward-Looking Statements**

All statements other than statements of historical fact included in this Form 10-Q including, without limitation, statements in this MD&A regarding our financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements within the meaning of Section 21E of the Exchange Act. When used in this Form 10-Q, words such as "expect," "anticipate," "estimate," "outlook," "project," "strategy," "intend," "plan," "target," "goal," "may," "will," "should," and "believe," and other variations or similar terminology and expressions identify forward-looking statements. Although we believe forward-looking statements are based upon reasonable assumptions, such statements involve known and unknown risks, uncertainties and other factors, many of which are beyond our control and difficult to predict, which may cause the actual results or performance of the Company to be materially different from any future results or performance expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to: general economic and financial conditions in the U.S. and globally; the potential effects of inflationary pressures, tariffs or the imposition of new tariffs, trade wars, barriers or restrictions, or threats of such actions, changes in interest rates, labor market shortages and supply chain issues; instability or volatility in financial markets or other unfavorable economic or business conditions caused by geopolitical concerns, including as a result of new or proposed legislation or regulatory, trade or other policies in or impacting the U.S., the conflict between Russia and Ukraine, the conflicts in Israel, Gaza and Iran, as well as any related uncertainty in the surrounding region, and the possible expansion of such conflicts; the effect of any of the foregoing on our customers' demand for our products and our suppliers' ability to manufacture and deliver our raw materials, including implications of reduced refinery utilization in the U.S.; our ability to sell and provide our goods and services; the ability of our customers to pay for our products; any closures of our and our customers' offices and facilities; risks associated with increased phishing, compromised business emails and other cybersecurity attacks, data privacy incidents and disruptions to our technology infrastructure; risks associated with potential use of artificial intelligence in our operations or those of third party service providers; risks associated with operating with a reduced workforce; risks associated with our indebtedness including compliance with financial and restrictive covenants, and our ability to access capital on reasonable terms, at a reasonable cost, or at all, due to economic conditions or otherwise; the impact of scheduled turnarounds and significant unplanned downtime and interruptions of production or logistics operations as a result of mechanical issues or other unanticipated events such as fires, severe weather conditions, natural disasters, pandemics, geopolitical conflicts and related events; price fluctuations, cost increases and supply of raw materials; our operations and growth projects requiring substantial capital; growth rates and cyclicality of the industries we serve including global changes in supply and demand; failure to develop and commercialize new products or technologies; loss of significant customer relationships; adverse trade and tax policies; extensive environmental, health and safety laws that apply to our operations; hazards associated with chemical manufacturing, storage and transportation; litigation associated with chemical manufacturing and our business operations generally; inability to acquire and integrate businesses, assets, products or technologies; protection of our intellectual property and proprietary information; prolonged work stoppages as a result of labor difficulties or otherwise; failure to maintain effective internal controls; our ability to declare and pay quarterly cash dividends and the amounts and timing of any future dividends; our ability to repurchase our common stock and the amount and timing of any future repurchases; disruptions in supply chain, transportation and logistics; potential for uncertainty regarding qualification for tax treatment of our spin-off; fluctuations in our stock price; and changes in laws or regulations applicable to our business. Forward-looking statements are not guarantees of future performance and actual results could differ materially from those contemplated by the forward-looking statements as a result of a number of risks, uncertainties and other factors including those noted above and those detailed in Item 1A of Part I and elsewhere in our 2025 Form 10-K, and subsequent reports filed with the SEC. All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. We do not undertake to update or revise any of our forward-looking statements.

**Business Overview**

AdvanSix is a vertically integrated chemistry company that produces essential materials for diverse end markets. Our value chain of our five U.S.-based manufacturing facilities plays a critical role in global supply chains and enables us to innovate and

------

deliver essential products for our customers across building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives, electronics and other end markets. Guided by our core values of Safety, Integrity, Accountability and Respect, AdvanSix strives to deliver best-in-class customer experiences and differentiated products in the industries of nylon solutions, plant nutrients and chemical intermediates. Our key product lines are as follows:

&nbsp;&nbsp;&nbsp;&nbsp;**• Nylon Solutions**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**◦ Nylon –** We sell our Nylon 6 resin globally, primarily under the Aegis® brand name. Nylon 6 is a polymer resin which is a synthetic material used by our customers to produce fibers, filaments, engineered plastics and films that, in turn, are used in such end-products as carpets, automotive and electric components, sports apparel, food packaging and other industrial applications.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ **Caprolactam –** Caprolactam is the key monomer used in the production of Nylon 6 resin. We internally polymerize caprolactam into Aegis® Nylon 6 Resin, and we also market and sell the caprolactam that is not consumed internally to customers who use it to manufacture polymer resins to produce fibers, compounds and other nylon products. Our Hopewell, VA manufacturing facility is one of the world's largest single-site producers of caprolactam as of March 31, 2026.

&nbsp;&nbsp;&nbsp;&nbsp;**• Plant Nutrients –** Our ammonium sulfate is used by customers as a fertilizer containing nitrogen and sulfur, two key plant nutrients. Ammonium sulfate fertilizer is derived from the integrated operations at the Hopewell manufacturing facility. Because of our Hopewell facility's size, scale and technology design, we are the world's largest single-site producer of ammonium sulfate fertilizer as of March 31, 2026. We market and sell ammonium sulfate primarily to North American and South American distributors, farm cooperatives and retailers to fertilize crops. We also manufacture sulfuric acid, ammonia and carbon dioxide as part of our integrated operations at Hopewell and occasionally sell any excess material not consumed internally to customers externally.

&nbsp;&nbsp;&nbsp;&nbsp;**• Chemical Intermediates –** We manufacture, market and sell a number of chemical intermediate products that are derived from the manufacturing processes within our integrated supply chain. Most significant is acetone which is used by our customers in the production of solvents, paints, coatings, adhesives, resins and herbicides. Other intermediate chemicals that we manufacture, market and sell include phenol, alpha-methylstyrene, cyclohexanone, oximes, cyclohexanol, and alkyl-amines and specialty amines. Additional end-products for intermediates include automotive components, and water treatment and pharmaceutical intermediates.

Global demand for Nylon 6 resin spans a variety of end-uses such as textiles, engineered plastics, industrial filament, food and industrial films, and carpet. The market growth typically tracks global GDP growth over the long-term but varies by end-use. We produce and sell caprolactam as a commodity product and produce and sell our Nylon 6 resin as both a commoditized and differentiated resin product. Our results of operations are primarily driven by production volume and the spread between the sales prices of our products and the costs of the underlying raw materials built into market-based and value-based pricing models. The global prices for nylon resin typically track a spread over the price of caprolactam, which in turn tracks as a spread over benzene because the key feedstock materials for caprolactam, phenol or cyclohexane, are derived from benzene. This price spread has historically experienced cyclicality as a result of global changes in supply and demand. Generally, Nylon 6 resin prices track the cyclicality of caprolactam prices, although prices set above the spread are achievable when nylon resin manufacturers, like AdvanSix, formulate and produce differentiated nylon resin products for current and new customer applications, such as our wire and cable and co-polymer offerings.

Global prices for ammonium sulfate fertilizer are influenced by several factors including the price of urea, which is the most widely used source of nitrogen-based fertilizer in the world. Other global factors driving ammonium sulfate fertilizer demand are general agriculture trends, including planted acres and the price of crops. Our ammonium sulfate product is positioned with the added value proposition of sulfur nutrition to increase yields of key crops. In addition, due to its nutrient density, the typical ammonium sulfate product delivers pound for pound the most readily available sulfur and nitrogen to crops as compared to other fertilizers. We also directly supply packaged ammonium sulfate to customers, primarily in North and South America, and have diversified and optimized our offerings to include spray-grade adjuvants to support crop protection, as well as other specialty fertilizers and products for industrial use.

Our ammonium sulfate fertilizer experiences quarterly sales seasonality reflecting both geographical and product sales mix considerations based on the timing and length of the growing seasons in North and South America. The North American fertilizer season typically runs from July, when the value chain begins restocking fertilizer, through June of the following year, when most application for the year's planting is completed. The new season fill begins in the third quarter and proceeds sequentially into the following spring, which is the peak period for crop fertilizer application. As a result of this pattern, North American ammonium sulfate demand and pricing, particularly for our higher-value granular product, are typically strongest in

------

the first half of the year through application for the spring crop and then decline in the second half of the year. Ammonium sulfate industry prices in the corn belt have declined approximately 12% from the second quarter to the third quarter, on average, since 2016. Due to the ammonium sulfate fertilizer sales cycle, we occasionally build up higher inventory balances because our production is continuous throughout the year and not tied to seasonal demand for fertilizers. Sales of most of our other products have generally been subject to minimal, or no, seasonality.

We also manufacture, market and sell a number of chemical intermediate products that are derived from the manufacturing processes within our integrated supply chain. Most significant is acetone, the price of which is influenced by its own supply and demand dynamics but can also be influenced by the underlying move in propylene input costs. Our differentiated product offerings include high-purity applications and high-value intermediates including our U.S. Amines portfolio as well as our oximes-based EZ-Blox™ anti-skinning agent used in paints and Nadone® cyclohexanone, which is a solvent used in various high-value applications.

We seek to run our production facilities on a nearly continuous basis for maximum efficiency as several of our intermediate products are key feedstock materials for other products in our integrated manufacturing chain. While our integration, scale and range of product offerings make us one of the most efficient manufacturers in our industry, these attributes also expose us to increased risk associated with material disruptions at any one of our production facilities or logistics operations which could impact the overall manufacturing supply chain. Further, although we believe that our sources of supply for our raw materials, including cumene, natural gas and sulfur, are generally robust, it is difficult to predict the impact that shortages, increased costs and related supply chain logistics considerations may have in the future. In order to mitigate the risk of unplanned interruptions, we schedule several planned plant turnarounds each year to conduct routine and major maintenance across our facilities. We also utilize maintenance excellence and mechanical integrity programs, targeted buffer inventory of intermediate chemicals necessary for our manufacturing process, and co-producer swap arrangements, which are intended to mitigate the extent of any production losses as a result of planned and unplanned downtime; however, the mitigation of all or part of any such production impact cannot be assured.

**Recent Developments**

*<u>Appointment of Senior Vice President and Chief Financial Officer</u>*

On April 13, 2026, the Company announced that its Board of Directors (the "Board") appointed Patrick C. Day as Senior Vice President and Chief Financial Officer, effective as of April 27, 2026, to succeed Christopher Gramm who had been serving as Interim Chief Financial Officer. Effective as of such date, Mr. Gramm returned to serving in his role as Vice President of Corporate Finance and Strategic Financial Planning and Analysis for the Company.

*<u>Anti-Dumping Duty Petition - Acetone</u>*

On November 4, 2024, the U.S. Department of Commerce ("Commerce") initiated the first five-year review of the anti-dumping orders on imports of acetone from Belgium, Singapore, South Africa, South Korea, and Spain. On November 1, 2024, the U.S. International Trade Commission ("ITC") issued its notice of initiation of its five-year review of the orders. The anti-dumping orders and applicable duties were set to continue for another five-year period if Commerce found that revocation of the orders would likely lead to continuation or recurrence of dumping and if the ITC found that revocation would likely lead to continuation or recurrence of material injury to the U.S. domestic industry. On March 7, 2025, Commerce determined that revocation of the anti-dumping orders would likely lead to continuation of recurrence of dumping. In January 2026, the ITC made affirmative determinations that revocation of the orders would likely lead to continuation or recurrence of material injury. As a result of Commerce and ITC's determinations, the orders were extended for another five years.

**<u>Results of Operations</u>**

(Dollars in thousands, unless otherwise noted)

**Sales**

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2026** | **2025** |
| Sales | $| 404183 | $377791 |
| % change compared with prior year period | 7.0% | 7.0% |  |

---

The change in sales compared to the prior year period is attributable to the following:

------

---

| | |
|:---|:---|
| | **Three Months Ended<br>March 31, 2026** |
| Volume | 6.0% |
| Price | 1.0% |
|  | 7.0% |

---

Sales increased in the three months ended March 31, 2026 compared to the prior year period by $26.4 million (approximately 7%) due primarily to (i) higher volume driven primarily by Chemical Intermediates sales (approximately 6%) and (ii) favorable market-based pricing (approximately 3%) primarily driven by an increase in Plant Nutrients reflecting higher nitrogen pricing amid increased sulfur input costs, partially offset by lower raw material pass through pricing following a net cost decrease in benzene and propylene (inputs to cumene which is a key feedstock to our products) (approximately 2%).

See Note 1. Organization, Operations and Basis of Presentation of Notes to the Condensed Consolidated Financial Statements for discussion of the additional reporting days in the current year period resulting from our normal quarterly closing procedures.

**Costs of Goods Sold**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2026** | **2025** | **2025** |
| Cost of goods sold | $| 400381 | $| 324320 |
| % change compared with prior year period | 23.5% | 23.5% |  |  |
| Gross Margin percentage | 0.9% | 0.9% | 14.2% | 14.2% |

---

Costs of goods sold increased in the three months ended March 31, 2026 compared to the prior year period by $76.1 million (approximately 23%) due primarily to (i) increased raw material costs (approximately 8%) driven by sulfur, (ii) $26 million of insurance proceeds (approximately 8% in the prior year period which did not recur in the current year period), (iii) increased sales volume (approximately 4%) and (iv) increased plant costs (approximately 4%) driven primarily by utility costs and winter storm related expenses.

Gross margin percentage decreased in the three months ended March 31, 2026 compared to the prior year period (approximately 13%) due primarily to (i) absence of insurance proceeds (approximately 6%), (ii) the impact of pricing, net of raw material costs (approximately 5%) and (iii) increased plant costs driven primarily by utility costs and winter storm related expenses (approximately 3%).

**Selling, General and Administrative Expenses**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2026** | **2025** | **2025** |
| Selling, general and administrative expenses | $| 22518 | $| 23409 |
| Percentage of Sales | 5.6% | 5.6% | 6.2% | 6.2% |

---

Selling, general and administrative expenses decreased by $0.9 million in the three months ended March 31, 2026 compared to the prior year period due primarily to the completion of the investment to upgrade our enterprise resource planning system in 2025.

**Income Tax Expense (Benefit)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2026** | **2025** | **2025** |
| Income tax expense (benefit) | $| (5131) | $| 5585 |
| Effective tax rate | 24.8% | 24.8% | 19.3% | 19.3% |

---

------

The Company's provision (benefit) for income taxes in interim periods is computed by applying an estimated annual effective tax rate against Income (loss) before taxes for the period in addition to recording any tax effects of discrete items for the quarter. The Company's effective tax rate for the three months ended March 31, 2026 and 2025 differed from the U.S. federal statutory rate due to state taxes and executive compensation deduction limitations which generally increase the rate, offset by research tax credits and the foreign-derived deduction eligible income (FDDEI) deduction (formerly known as the foreign-derived intangible income (FDII) deduction) that generally decrease the rate. During the three months ended March 31, 2025, discrete tax adjustments recorded in the quarter related to Internal Revenue Code (IRC) Section 45Q tax credits of $1.8 million, offset slightly by state tax legislation changes, resulted in a net 5.8% decrease in the Effective tax rate.

The Company's effective tax rate for the three months ended March 31, 2026 was higher than the prior year period due primarily to the discrete tax adjustments related to IRC Section 45Q tax credits and state tax legislative changes in the prior year quarter described above.

On July 4, 2025, the One Big Beautiful Bill Act (the "Act") was enacted into law which includes numerous tax provisions affecting businesses, including the reinstatement of full expensing of domestic research and experimental expenditures, modification of the limitation on business interest and making permanent full expensing for certain business property. Several of the major business provisions in the Act became effective in 2025 while other business tax changes are effective for the 2026 tax year. The major business provisions in the Act reduced our cash taxes in 2025 and are expected to reduce our cash taxes in 2026 and future periods.

**Net Income**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| Net income (loss) | $(15546) | $23344 |

---

As a result of the factors described above, Net income (loss) was ($15.5) million for the three months ended March 31, 2026 as compared to $23.3 million in the corresponding prior year period.

**<u>Non-GAAP Measures</u>**

(Dollars in thousands, unless otherwise noted)

The following tables set forth the non-GAAP financial measures of Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net income and Adjusted EPS. Adjusted EBITDA is defined as Net income before Interest, Income taxes, Depreciation and amortization, Non-cash stock-based compensation, Non-recurring, unusual or extraordinary expenses, Non-cash amortization from acquisitions and Strategic advisory and professional fees that are not reflective of ongoing operations. Adjusted EBITDA Margin is equal to Adjusted EBITDA divided by Sales. The following tables may also present each of these measures as further adjusted. The Company believes these non-GAAP financial measures provide meaningful supplemental information as they are used by the Company's management to evaluate the Company's operating performance, enhance a reader's understanding of the financial performance of the Company, and facilitate a better comparison among fiscal periods and performance relative to the Company's competitors, as the non-GAAP measures exclude items that management believes do not reflect the Company's ongoing operations.

These non-GAAP results are presented for supplemental informational purposes only and should not be considered a substitute for the financial information presented in accordance with U.S. GAAP. Non-GAAP financial measures should be read only in conjunction with the comparable U.S. GAAP financial measures. The Company's non-GAAP measures may not be comparable to other companies' non-GAAP measures.

The following is a reconciliation between the non-GAAP financial measures of Adjusted Net income, Adjusted EBITDA and Adjusted EBITDA Margin to their most directly comparable U.S. GAAP financial measure:

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2026** | **2025** | **2025** |
| Net income (loss) | $| (15546) | $| 23344 |
| Non-cash stock-based compensation | 2045 | 2045 | 1978 | 1978 |
| Non-recurring, unusual or extraordinary expense |  |  |  |  |
| Non-cash amortization from acquisitions | 532 | 532 | 532 | 532 |
| Strategic advisory and professional fees |  |  |  |  |
| Income tax benefit relating to reconciling items | (440) | (440) | (430) | (430) |
| Adjusted Net income (loss) (non-GAAP) | (13409) | (13409) | 25424 | 25424 |
| Interest expense, net | 2430 | 2430 | 1541 | 1541 |
| Income tax expense (benefit) - Adjusted | (4691) | (4691) | 6015 | 6015 |
| Depreciation and amortization - Adjusted | 20426 | 20426 | 18646 | 18646 |
| Adjusted EBITDA (non-GAAP) | $| 4756 | $| 51626 |
| Sales | $| 404183 | $| 377791 |
| Adjusted EBITDA Margin\* (non-GAAP) | 1.2% | 1.2% | 13.7% | 13.7% |

---

*\* Adjusted EBITDA Margin is defined as Adjusted EBITDA divided by Sales.*

The following is a reconciliation between the non-GAAP financial measures of Adjusted EPS to its most directly comparable U.S. GAAP financial measure:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| Net income (loss) | $(15546) | $23344 |
| Adjusted Net income (loss) (non-GAAP) | (13409) | 25424 |
| Weighted-average number of common shares outstanding - basic | 26980742 | 26838146 |
| Dilutive effect of equity awards and other stock-based holdings |  | 450998 |
| Weighted-average number of common shares outstanding - diluted | 26980742 | 27289144 |
| EPS - Basic | $(0.58) | $0.87 |
| EPS - Diluted | $(0.58) | $0.86 |
| Adjusted EPS - Basic (non-GAAP) | $(0.50) | $0.95 |
| Adjusted EPS - Diluted (non-GAAP) | $(0.50) | $0.93 |

---

**<u>Liquidity and Capital Resources</u>**

(Dollars in thousands, unless otherwise noted)

**Liquidity**

We believe that cash balances and operating cash flows, together with available capacity under our credit agreement, as utilized in the first quarter of 2026, will provide adequate funds to support our current short-term operating objectives as well as our longer-term strategic plans, subject to the risks and uncertainties outlined below, in our "Note Regarding Forward-Looking Statements" above, and in the risk factors previously disclosed in Item 1A of Part I of our 2025 Form 10-K. Our principal

------

source of liquidity is our cash flow generated from operating activities, which is expected to provide us with the ability to meet the majority of our short-term funding requirements for the next twelve months and beyond. Our cash flows are affected by capital requirements and production volume, which may be materially impacted by unanticipated events such as unplanned downtime, material disruptions at our production facilities, the prices of our raw materials, general economic and industry trends and customer demand. The Company applies a proactive and disciplined approach to working capital management to optimize cash flow and to enable capital allocation options in support of the Company's strategy. We utilize supply chain financing and trade receivables discount arrangements with third-party financial institutions which optimize terms and conditions related to accounts receivable and accounts payable in order to enhance liquidity and enable us to efficiently manage our working capital needs. Although we continue to optimize supply chain financing and trade receivable programs in the ordinary course, our utilization of these arrangements has not had a material impact on our liquidity. In addition, we monitor the third-party depository institutions that hold our cash and cash equivalents. Our emphasis is primarily on the safety of principal and secondarily on maximizing yield on those funds. We diversify our cash and cash equivalents among counterparties to minimize exposure to any one of these entities.

On a recurring basis, our primary future cash needs will be centered on operating activities, working capital, capital expenditures, dividends and liquidity reflecting disciplined capital deployment. Capital expenditures are deployed for various ongoing investments and initiatives to improve reliability, yield and quality, expand production capacity and comply with health, safety and environmental ("HSE") regulations. We believe that our future cash from operations, cash on hand and available capacity under our credit agreement, as well as our access to credit and capital markets, will provide adequate resources to fund our expected operating and financing needs and obligations. Our ability to fund our capital needs, however, will depend on our ongoing ability to generate cash from operations and access to credit and capital markets, both of which are subject to the risk factors previously disclosed in Item 1A of Part I of our 2025 Form 10-K, as well as general economic, financial, competitive, regulatory and other factors that are beyond our control.

As of the end of the first quarter of 2026, the Company had approximately $17.6 million of cash on hand with approximately $229 million of additional capacity available under the revolving credit facility. The Company's Consolidated Leverage Ratio financial covenant of its credit facility allows it to net up to $75 million of cash with debt. Capital expenditures are expected to be approximately $75 million to $95 million in 2026 compared to $116 million in 2025, reflecting a risk-based prioritization of base investments and enterprise programs with continued progression of growth programs including our SUSTAIN program.

We assumed from Honeywell International Inc. ("Honeywell") all HSE liabilities and compliance obligations related to the past and future operations of our current business as of the spin-off, as well as all HSE liabilities associated with the three manufacturing locations assumed from Honeywell that are used in our current operations, including any cleanup or other liabilities related to any contamination that may have occurred at such locations in the past. Honeywell retained all HSE liabilities related to former business locations or the operation of our former businesses. Although we have ongoing environmental remedial obligations at certain of our facilities, in the past three years, the associated remediation costs have not been material, and we do not expect our known remediation costs to have a material adverse effect on the Company's consolidated financial position or results of operations.

We expect that our primary cash requirements for 2026 will be to fund costs associated with ongoing operations, capital expenditures, and amounts related to other contractual obligations.

The Company made no cash contributions to the defined benefit pension plan during the three months ended March 31, 2026 as there were no funding requirements for the period. Additional contributions may be made in future periods sufficient to satisfy pension funding requirements in those periods or on a discretionary basis.

As of March 31, 2026, the Company has repurchased a total of 6,386,289 shares of common stock life-to-date, including 1,140,833 shares withheld to cover tax withholding obligations in connection with the vesting of awards, for an aggregate of $195.4 million at a weighted average market price of $30.59 per share. As of March 31, 2026, approximately $62.0 million remained available for share repurchases under the current authorization approved by the Board on February 17, 2023. During the period April 1, 2026 through May 1, 2026, no additional shares were repurchased for tax withholding obligations or under the currently authorized repurchase program.

Repurchases may be made from time to time on the open market in accordance with Rule 10b-18 of the Exchange Act, including through the use of trading plans intended to qualify under Rule 10b5-1 of the Exchange Act. The size and timing of these repurchases will depend on pricing, market and economic conditions, legal and contractual requirements and other factors. The share repurchase program has no expiration date and may be modified, suspended or discontinued at any time. The par value of the shares repurchased is applied to Treasury stock and the excess of the purchase price over par value is applied to Additional paid-in capital.

------

As of March 31, 2026, the Company did not have any off-balance sheet arrangements as described in Instruction 8 to Item 303(b) of Regulation S-K and did not have any material changes in the commitments or contractual obligations detailed in the 2025 Form 10-K (see Part II, Item 7 "Management's Discussion and Analysis of Financial Condition and Results of Operations" under "Liquidity and Capital Resources - Liquidity"). The Company has not guaranteed any debt or commitments of other entities or entered into any options on non-financial assets.

*<u>Dividends</u>*

The Company commenced the declaration of dividends on September 28, 2021.

Dividends paid during 2026 and the dividend announced on the date of this filing are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Date of Announcement** | **Date of Record** | **Date Payable** | **Dividend per Share** | **Total Approximate Dividend Amount<br>($M)** |
| 5/8/2026 | 5/19/2026 | 6/2/2026 | $0.16 | $4.3 |
| 2/20/2026 | 3/9/2026 | 3/23/2026 | $0.16 | $4.3 |

---

The timing, declaration, amount and payment of future dividends to stockholders, if any, will fall within the discretion of our Board. Holders of shares of our common stock will be entitled to receive dividends when, and if, declared by our Board at its discretion out of funds legally available for that purpose, subject to the terms of our indebtedness, the preferential rights of any preferred stock that may be outstanding, legal requirements, regulatory constraints, industry practice and other factors that our Board deems relevant.

**Credit Agreement**

On October 27, 2021, the Company entered into a Credit Agreement, as amended on June 27, 2023 (the "Credit Agreement"), among the Company, the lenders party thereto, the swing line lenders party thereto, the letter of credit issuers party thereto and Truist Bank, as administrative agent, which provides for a senior secured revolving credit facility in an aggregate principal amount of $500 million (the "Revolving Credit Facility").

Borrowings under the Revolving Credit Facility are subject to customary borrowing conditions.

The Revolving Credit Facility provided for a scheduled maturity date of October 27, 2026 (which was extended to such date pursuant to an October 2025 amendment, as described in more detail below). The Credit Agreement permits the Company to utilize up to $40 million of the Revolving Credit Facility for the issuance of letters of credit and up to $40 million for swing line loans. The Company has the option to establish a new class of term loans and/or increase the amount of the Revolving Credit Facility in an aggregate principal amount for all such incremental term loans and increases of the Revolving Credit Facility of up to the sum of (x) $175 million plus (y) an amount such that the Company's Consolidated First Lien Secured Leverage Ratio (as defined in the Credit Agreement) would not be greater than 2.75 to 1.00, in each case, to the extent that any one or more lenders, whether or not currently party to the Credit Agreement, commits to be a lender for such amount or any portion thereof.

Borrowings under the Credit Agreement bear interest at a rate equal to either the sum of a base rate plus a margin ranging from 0.25% to 1.25% or the sum of an Adjusted Term SOFR rate plus a margin ranging from 1.25% to 2.25%, with either such margin varying according to the Company's Consolidated Leverage Ratio (as defined in the Credit Agreement). The Company is also required to pay a commitment fee in respect of unused commitments under the Revolving Credit Facility, if any, at a rate ranging from 0.15% to 0.35% per annum depending on the Company's Consolidated Leverage Ratio.

Substantially all tangible and intangible assets of the Company and its domestic subsidiaries are pledged as collateral to secure the Company's obligations under the Credit Agreement.

The Credit Agreement contains customary covenants limiting the ability of the Company and its subsidiaries to, among other things, pay cash dividends, incur debt or liens, redeem or repurchase stock of the Company, enter into transactions with affiliates, make investments, make capital expenditures, merge or consolidate with others or dispose of assets. The Credit Agreement also contains financial covenants that require the Company to maintain a Consolidated Interest Coverage Ratio (as defined in the Credit Agreement) of not less than 3.00 to 1.00 and to maintain a Consolidated Leverage Ratio of (ii) 3.75 to 1.00 or less (subject to the Company's option to elect a consolidated leverage ratio increase in connection with certain acquisitions).

------

If the Company does not comply with the covenants in the Credit Agreement, the lenders may, subject to customary cure rights, require the immediate payment of all amounts outstanding under the Revolving Credit Facility. We were in compliance with all of our covenants at March 31, 2026 and through the date of the filing of this Form 10-Q.

On October 23, 2025, the Company entered into Amendment No. 2 (the "Amendment") to the Credit Agreement, (as further amended by the Amendment, the "Amended Credit Agreement"), among the Company, the guarantors, the lenders party thereto and Truist Bank, as administrative agent.

Pursuant to the Amendment, the Credit Agreement was amended to, among other things: (i) extend the maturity date of the Revolving Credit Facility for participating Revolving Credit Lenders, as defined in the Amended Credit Agreement, in an aggregate principal amount of $452 million to the earlier of (x) October 27, 2027 and (y) the date of the termination in whole of the Revolving Credit Facility, pursuant to the terms of the Amended Credit Agreement, and (ii) effect certain other conforming changes and modifications consistent with the foregoing. The remaining $48 million under the Revolving Credit Facility that was not extended will continue to mature on the earlier of (x) October 27, 2026 and (y) the date of the termination in whole of the Revolving Credit Facility pursuant to the terms of the Amended Credit Agreement. The Company expects to refinance the Revolving Credit Facility before such maturity date.

We had a borrowed balance of $215 million under the Revolving Credit Facility at December 31, 2025. We borrowed an incremental net amount of $55 million during the three months ended March 31, 2026, bringing the balance under the Revolving Credit Facility to $270 million, and available credit for use of approximately $229 million as of March 31, 2026. We expect that Cash provided by operating activities will fund future interest payments on the Company's outstanding indebtedness.

**Cash Flow Summary**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| Cash provided by (used for): |  |  |
| &nbsp;&nbsp;Operating activities | $(15332) | $11443 |
| &nbsp;&nbsp;Investing activities | (36163) | (36794) |
| &nbsp;&nbsp;Financing activities | 49303 | 14131 |
| Net change in cash and cash equivalents | $(2192) | $(11220) |

---

Cash provided by operating activities decreased by $26.8 million for the three months ended March 31, 2026 versus the prior year period due primarily to (i) a $38.9 million decrease in Net income, (ii) a $10.2 million unfavorable impact from Accrued liabilities and (iii) an unfavorable impact of $7.5 million from Deferred income taxes. These net unfavorable impacts were partially offset by a $30.3 million favorable cash impact from working capital (comprised of Accounts and other receivables, Inventories, Accounts payable and Deferred income and customer advances).

Cash used for investing activities decreased by $0.6 million for the three months ended March 31, 2026 versus the prior year period due primarily to the timing of cash payments on capital expenditures following prior quarter outages and disciplined spending on replacement maintenance while maintaining progress on growth and other enterprise programs.

Cash provided by financing activities increased by $35.2 million for the three months ended March 31, 2026 versus the prior year period due primarily to net borrowings of $55.0 million during the three months ended March 31, 2026 compared to net borrowings of $20.0 million during the prior year period.

**<u>Capital Expenditures</u>**

(Dollars in thousands, unless otherwise noted)

Our operations are capital intensive, requiring ongoing investments that have consisted, and are expected to continue to consist, primarily of capital expenditures required to maintain and improve equipment reliability, expand production output, further improve mix, yield and cost position, and comply with environmental and safety regulations.

The following table summarizes ongoing and expansion capital expenditures:

------

---

| | |
|:---|:---|
| | **Three Months Ended<br>March 31, 2026** |
| Capital expenditures in Accounts payable at December 31, 2025 | $26670 |
| Purchases of property, plant and equipment | 20272 |
| Less: Capital expenditures in Accounts payable at March 31, 2026 | (11006) |
| Cash paid for capital expenditures | $35936 |

---

For 2026, we expect our total capital expenditures to be approximately $75 million to $95 million as discussed in the Liquidity section above.

**<u>Critical Accounting Policies and Estimates</u>**

The preparation of our Condensed Consolidated Financial Statements in accordance with U.S. GAAP is based on the selection and application of accounting policies that require us to make significant estimates and assumptions about the effects of matters that are inherently uncertain. We consider these accounting policies to be critical to the understanding of our Condensed Consolidated Financial Statements. For a full description of our critical accounting policies, refer to Management's Discussion and Analysis of Financial Condition and Results of Operations contained in our 2025 Form 10-K. While there have been no material changes to our critical accounting policies, or the methodologies or assumptions we apply under them since the filing of the 2025 Form 10-K, we continue to monitor such methodologies and assumptions.

**<u>Recent Accounting Pronouncements</u>**

See "Note 2. Recent Accounting Pronouncements" to the Condensed Consolidated Financial Statements included in Part I. Item 1 of this Form 10-Q.

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

**Interest Rate Risk**

Our exposure to risk based on changes in interest rates during the three-month period ended March 31, 2026 relates primarily to the Revolving Credit Facility. The Revolving Credit Facility bears interest at floating rates. For variable rate debt, interest rate changes generally do not affect the fair market value of such debt assuming all other factors remain constant but do impact future earnings and cash flows. Accordingly, we may be exposed to interest rate risk on borrowings under the Credit Agreement.

Based on current borrowing levels at March 31, 2026, a 25-basis point fluctuation in interest rates for the three months ended March 31, 2026 would have resulted in an increase or decrease to our interest expense of approximately $0.7 million.

See "Note 2. Summary of Significant Accounting Policies" to the Consolidated Financial Statements included in Item 8 of our 2025 Form 10-K for a discussion relating to credit and market, commodity price and interest rate risk management.

**ITEM 4. CONTROLS AND PROCEDURES**

**Evaluation of Disclosure Controls and Procedures**

The Company maintains disclosure controls and procedures designed to provide reasonable assurance that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.

Management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives. Because there are inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud have been, or will be, detected.

------

Our Chief Executive Officer and Chief Financial Officer, with the assistance of other members of our management, conducted an evaluation of the effectiveness of the Company's disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this quarterly report. Based upon such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are effective at a reasonable assurance level as of March 31, 2026, the end of the period covered by this quarterly report.

**Changes in Internal Control over Financial Reporting**

Management has not identified any change in the Company's internal control over financial reporting that occurred during the quarter ended March 31, 2026 that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

**PART II. OTHER INFORMATION**

**ITEM 1. LEGAL PROCEEDINGS**

As previously reported, the Virginia Department of Environmental Quality ("VA DEQ") initiated discussions with the Company regarding certain alleged violations associated with air emissions at the Company's Hopewell facility. The Company entered into an Order by Consent with the VA DEQ in March 2026, which provided for a civil charge of $2,036,668, of which $25,000 would be paid to the VA DEQ, and the remaining $2,011,668 would be satisfied through (i) supplemental environmental projects protecting the ecosystems and the environment by performing NOx emission reduction capital projects with a required completion date of December 31, 2027 and (ii) paying $250,000 to the VA DEQ for design and/or implementation of wastewater treatment facility measures at the Hopewell Regional Wastewater Treatment Facility.

From time to time, we are involved in litigation relating to claims arising outside of the ordinary course of our business operations. We are not a party to, and, to our knowledge, there are no pending claims or actions against us, the ultimate disposition of which could be expected to have a material adverse effect on our consolidated financial position, results of operations or operating cash flows.

**ITEM 1A. RISK FACTORS**

There have been no material changes to our risk factors as previously disclosed in Item 1A of Part I of the 2025 Form 10-K, which are hereby incorporated by reference.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

On May 4, 2018, the Company announced that the Board authorized a share repurchase program of up to $75 million of the Company's common stock. On February 22, 2019, the Company announced that the Board authorized a share repurchase program of up to an additional $75 million of the Company's common stock, which was in addition to the remaining capacity authorized under the May 2018 share repurchase program. On February 17, 2023, the Company announced that the Board authorized a share repurchase program of up to an additional $75 million of the Company's common stock, which was in addition to the remaining capacity available under the previously approved share repurchase program. Repurchases may be made from time to time on the open market in accordance with Rule 10b-18 of the Exchange Act, including through the use of trading plans intended to qualify under Rule 10b5-1 of the Exchange Act. The size and timing of these repurchases will depend on pricing, market and economic conditions, legal and contractual requirements and other factors. The repurchase program has no expiration date and may be modified, suspended or discontinued at any time.

The below table sets forth the repurchases of Company common stock, by month, for the quarter ended March 31, 2026. During the quarter ended March 31, 2026, no additional shares were purchased under our share repurchase program and 72,500 shares were withheld to cover tax withholding obligations in connection with the vesting of equity awards.

------

**ISSUER PURCHASES OF EQUITY SECURITIES**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Period** | | **Total Number of Shares Purchased** | **Average Price Paid per Share** | **Total Number of Shares Purchased as Part of Publicly Announced Plan** | **Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plan** |
| January 2026 |  |  | $— |  | $61957898 |
| February 2026 |  |  |  |  | 61957898 |
| March 2026 | (1) | 72500 | 17.60 |  | 61957898 |
| Total |  | 72500 | $17.60 |  |  |

---

(1) Total number of shares purchased includes 72,500 shares covering tax withholding obligations in connection with the vesting of equity awards

During the period April 1, 2026 through May 1, 2026, no additional shares were repurchased for tax withholding obligations or under the currently authorized repurchase program.

**ITEM 5. OTHER INFORMATION**

**Insider Rule 10b5-1 Trading Plans**

On March 13, 2026, Achilles B. Kintiroglou, the Company's Senior Vice President, General Counsel and Corporate Secretary, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The plan provides for the sale of 2,000 shares and the exercise and sale of 2,530 stock options. Mr. Kintiroglou's plan will expire on March 5, 2027.

On March 13, 2026, Erin N. Kane, the Company's President and Chief Executive Officer, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The plan provides for the sale of 52,500 shares and the exercise and sale of 53,688 stock options. Ms. Kane's plan will expire on March 5, 2027.

------

**ITEM 6. EXHIBITS**

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 3.1 | <u>[Amended and Restated Certificate of Incorporation of AdvanSix Inc. (conformed copy) (incorporated by reference to Exhibit 3.1 to the Company's Quarterly Report on Form 10-Q filed on August 1, 2025)](https://www.sec.gov/Archives/edgar/data/1673985/000167398525000119/exhibit31_conformedarcerti.htm)</u> |
| 3.2 | <u>[Amended and Restated By-laws of AdvanSix Inc. (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on June 20, 2023).](https://www.sec.gov/Archives/edgar/data/1673985/000167398523000091/exhibit31amendedandrestate.htm)</u> |
| 31.1 | <u>[Rule 13a-14(a)/15d-14(a) Certification of the Company's Principal Executive Officer.](a10q2026exhibit311ceo.htm)</u> |
| 31.2 | <u>[Rule 13a-14(a)/15d-14(a) Certification of the Company's Principal Financial Officer.](a10q2026exhibit312cfo.htm)</u> |
| 32.1 | <u>[Section 1350 Certification of the Company's Principal Executive Officer. The information contained in this Exhibit shall not be deemed filed with the SEC nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.](a10q2026exhibit321ceosox.htm)</u> |
| 32.2 | <u>[Section 1350 Certification of the Company's Principal Financial Officer. The information contained in this Exhibit shall not be deemed filed with the SEC nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.](a10q2026exhibit322cfosox.htm)</u> |
| 101.INS | Inline XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document. |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and included in Exhibit 101) |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | ADVANSIX INC. | ADVANSIX INC. |
| Date: May 8, 2026 | By: | /s/ Patrick C. Day |
|  |  | **Patrick C. Day** |
|  |  | **Senior Vice President and Chief Financial Officer** |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATIONS**

I, Erin N. Kane, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this Quarterly Report on Form 10-Q of AdvanSix Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 8, 2026

---

| |
|:---|
| /s/ Erin N. Kane |
| Erin N. Kane |
| President and Chief Executive Officer |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATIONS**

I, Patrick C. Day, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this Quarterly Report on Form 10-Q of AdvanSix Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 8, 2026

---

| |
|:---|
| /s/ Patrick C. Day |
| Patrick C. Day |
| Senior Vice President and Chief Financial Officer |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350**

**AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of AdvanSix Inc. (the "Company") on Form 10-Q for the period ended March 31, 2026, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of her knowledge:

1.&nbsp;&nbsp;&nbsp;&nbsp;the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.&nbsp;&nbsp;&nbsp;&nbsp;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: &nbsp;&nbsp;&nbsp;&nbsp;May 8, 2026

---

| |
|:---|
| /s/ Erin N. Kane |
| Erin N. Kane |
| President and Chief Executive Officer |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350**

**AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of AdvanSix Inc. (the "Company") on Form 10-Q for the period ended March 31, 2026, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

1.&nbsp;&nbsp;&nbsp;&nbsp;the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2.&nbsp;&nbsp;&nbsp;&nbsp;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:&nbsp;&nbsp;&nbsp;&nbsp;May 8, 2026

---

| |
|:---|
| /s/ Patrick C. Day |
| Patrick C. Day |
| Senior Vice President and Chief Financial Officer |

---

<br>